Patents Examined by Jane Zara
  • Patent number: 9861574
    Abstract: Methods of inhibiting the growth of cells or inducing cell death by contacting the cells with or introducing into the cells a composition including a 5? triphosphate, 2? fluoro-modified pyrimidine non-linear single stranded RNA at least 17 nucleotides long with a least 3 base pairings or a 5? triphosphate, 2? fluoro-modified double stranded RNA at least 17 base pairs long in an amount effective to inhibit cell growth, induce cell death or induce cytokine production by the cells. The methods also include administration of the compositions to a subject. The subject may have a proliferative disorder or infectious disease and administration of the compositions provided herein may treat the disorder or disease.
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: January 9, 2018
    Assignee: Duke University
    Inventors: Jaewoo Lee, Johannes Urban, Bruce A. Sullenger
  • Patent number: 9833467
    Abstract: Provided herein are methods of treating or preventing a bone disorder in a subject.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: December 5, 2017
    Assignee: UNIVERSITY OF ROCHESTER
    Inventor: Roman A. Eliseev
  • Patent number: 9828606
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: November 28, 2017
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Patent number: 9821034
    Abstract: The present disclosure relates to a method for treatment or prevention of diseases have an increased level of insulin-like growth factor I (IGF-I). The method comprises administration of a growth hormone (GH) variant having antagonistic activity in combination with an oligonucleotide targeted to growth hormone receptor (GHR) to a subject in need.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: November 21, 2017
    Assignee: Antisense Therapeutics Ltd
    Inventor: George Tachas
  • Patent number: 9822360
    Abstract: The present disclosure relates to RNA amidates and thioamidates useful for RNA interference applications. The RNA amidates and thioamidates contain at least one internucleoside linkage chosen from ribo-N3??P5? phosphoramidate (NP) and ribo-N3??P5? thiophosphoramidate (NPS) linkages, and optionally further containing at least one covalently conjugated lipid moiety. Compositions comprising the amidates and thioamidates are disclosed, as are methods for their use in modulating gene expression.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: November 21, 2017
    Assignee: Geron Corporation
    Inventors: Sergei Gryaznov, Krisztina Pongracz
  • Patent number: 9816089
    Abstract: A method of reducing the level of a transcription product in a cell comprising contacting with the cell a composition comprising a double-stranded nucleic acid complex comprising a first nucleic acid strand annealed to a second nucleic acid strand, wherein: (i) the first nucleic acid strand hybridizes to the transcription product and comprises (a) a region consisting of at least 4 consecutive nucleotides that are recognized by RNase H when the strand is hybridized to the transcription product, (b) one or more nucleotide analogs located on 5? terminal side of the region, (c) one or more nucleotide analogs located on 3? terminal side of the region and (d) a total number of nucleotides and nucleotide analogs ranging from 8 to 35 nucleotides and (ii) the second nucleic acid strand comprises (a) nucleotides and optionally nucleotide analogs and (b) at least 4 consecutive RNA nucleotides.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: November 14, 2017
    Assignees: National University Corporation Tokyo Medical and Dental University, Osaka University
    Inventors: Takanori Yokota, Kazutaka Nishina, Satoshi Obika, Hidehiro Mizusawa
  • Patent number: 9796756
    Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cell in vivo. The pharmacokinetic modulator improve in vivo targeting compared to the targeting ligand alone. Targeting ligand-pharmacokinetic modulator targeting moiety targeted RNAi polynucleotides can be administered in vivo alone or together with co-targeted delivery polymers.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: October 24, 2017
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Philipp Hadwiger, Torsten Hoffmann, Eric A Kitas, Peter Mohr, Ingo Roehl, Linda Valis, David B Rozema, David L Lewis, Darren H Wakefield
  • Patent number: 9790496
    Abstract: Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modification patterns that yield potent inhibitors of miR-21 activity. The compositions may be used to inhibit miR-21, and also to treat diseases associated with abnormal expression of miR-21, such as fibrosis and cancer.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: October 17, 2017
    Assignee: Regulus Therapeutics Inc.
    Inventor: Balkrishen Bhat
  • Patent number: 9783805
    Abstract: In some embodiments, an antiviral vector is provided. The antiviral vector includes a replication competent adeno-associated virus (AAV) and an inhibitory expression cassette that includes a nucleotide sequence that encodes an RNAi molecule that inhibits expression of a targeted helper virus (THV) gene. The THV gene may be part of an Adenovirus (Ad) genome, a Human Papillomavirus (HPV) genome, a Human Herpes Virus (HHV) genome, or a Vaccinia virus (W) genome.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: October 10, 2017
    Assignee: CITY OF HOPE
    Inventors: Kamehameha K. Wong, Jr., Cam Mroske, Saswati Chatterjee
  • Patent number: 9783801
    Abstract: The invention relates to the control of gene expression. Specifically, the invention provides compositions and methods for the production and use of recombinant nucleic acid molecules that have the ability to specifically downregulate an expressed target gene in vivo. In some aspects, the invention provides methods for producing a hairpin DNA molecule where part of the molecule is derived from an mRNA that is a target for a small interfering RNA (siRNA) derived from the hairpin. In other aspects, the invention provides synthetic hairpin adapter oligonucleotides that are used in the construction of siRNA-producing cassettes. In other aspects, the invention provides methods for testing for the presence or absence of specific inhibitory activity of an RNAi trigger molecule, and in still other aspects, the invention provides methods for identifying an active RNAi trigger molecule from a library of RNAi trigger molecules.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: October 10, 2017
    Assignee: BerGenBio ASA
    Inventors: David Micklem, James Lorens
  • Patent number: 9784726
    Abstract: A method of screening for a candidate compound for the treatment of a condition involving dysregulation of metabolism in a mammal, said method comprising bringing a compound into contact with at least one population of cells, comprising cells that express mTOR and Akt and that are capable of activating mTORC2 and Akt; determining mTORC2 activity and Akt activity in cells brought into contact with the compound, and identifying the candidate compound based on the determined mTORC2 activity and Akt activity. A kit for use in such a method of. A compound for use in a method of treatment of a condition involving dysregulation of metabolism in a mammal, and a method of treatment of such a condition.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: October 10, 2017
    Assignee: ATROGI AB
    Inventor: Tore Bengtsson
  • Patent number: 9772324
    Abstract: The present invention relates to the use of inhibitors of leukotriene B4 receptor BLT2 for treating asthma. More particularly, the present invention relates to a pharmaceutical composition for treating asthma comprising BLT2 inhibitors and a method for treating asthma using BLT2 inhibitors.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: September 26, 2017
    Assignee: Korea University Research and Business Foundation
    Inventor: Jae-Hong Kim
  • Patent number: 9764035
    Abstract: Treatment of prostate cancer by regional and prolonged release of one or more nucleotide-based RNAi agents is provided.
    Type: Grant
    Filed: March 29, 2015
    Date of Patent: September 19, 2017
    Assignee: SILENSEED LTD.
    Inventors: Amotz Shemi, Elina Zorde Khvalevsky, Rachel Malka Gabai
  • Patent number: 9765333
    Abstract: The present invention provides compositions comprising siRNA molecules that target Marburg virus (MARV) gene expression, lipid particles comprising one or more (e.g., a combination) of the siRNA molecules, and methods of delivering and/or administering the lipid particles, for the purposes of treating MARV infection.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: September 19, 2017
    Assignee: PROTIVA BIOTHERAPEUTICS, INC.
    Inventors: Raul J. Ursic Bedoya, Ian MacLachlan, Marjorie Ann Robbins
  • Patent number: 9758811
    Abstract: The present invention is a method for measuring the amount of at least one molecule in a biological sample, the method comprising a) combining the sample, or a derivative thereof, with one or more aptamers and allowing one or more molecules in the sample to bind to the aptamer(s); b) separating bound from unbound molecules; and c) quantifying the molecule(s) bound to the or each aptamer, wherein quantification of the bound molecule(s) is carried out by sequencing at least part of the or each aptamer. Uses of and products derived from the method are also contemplated.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: September 12, 2017
    Assignee: Caris Life Sciences Switzerland Holdings GmbH
    Inventors: Clive Gavin Brown, Koen Kas, Sven Agnes Jan Eyckerman
  • Patent number: 9758835
    Abstract: Embodiments provide methods and compositions related to detecting neoplasia in ulcerative colitis patients by detection and analysis of the methylation state of miR-1, -9, -124, miR-137 and/or miR-34b/c in samples from UC patients.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: September 12, 2017
    Assignee: Baylor Research Institute
    Inventors: Ajay Goel, Yuji Toiyama, C. Richard Boland, Yoshinaga Okugawa
  • Patent number: 9753031
    Abstract: A device for identifying the presence of a specific target molecule or biomarker by the detection of a change in an electrical property includes a measurement sensor 8 comprising a semiconducting sensor structure 12 capable of conjugating with the biomarker, thus giving rise to the said change in electrical property, and an electrode system 3, 4 for conducting a signal from the device. According to the invention there is a further such sensor 9, of substantially identical form but having its sensor structure 14 already conjugated with the biomarker, or otherwise capped, e.g. using a further oligonucleotide strand, so as to act as an internal reference. When a biological sample, e.g. saliva, is applied to the electrodes, the reference enables the discounting of all environmental effects other than the biomarker. The invention provides a simple, cheap and accurate text for one or more biomarkers that can be used in the field without complex equipment.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: September 5, 2017
    Assignee: Sapient Sensors Limited
    Inventors: Stephen Lee Cash, Keith Robson, Ian Anthony Kinloch, Peter George Stockley
  • Patent number: 9752148
    Abstract: An isolated plant-functional microRNA or an extract containing said plant-functional microRNA, a preparation method therefor, and an application thereof are provided. The plant-functional microRNA originates from the endogenous microRNA of a plant, is present in a water-soluble and/or fat-soluble extract of said plant, and is capable of regulating non-plant target-genes.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: September 5, 2017
    Assignee: Micromedmark Biotech Co., Ltd.
    Inventors: Chenyu Zhang, Junfeng Zhang, Ke Zeng, Lei Dong
  • Patent number: 9744237
    Abstract: Methods and systems are described for a rapid and sustainable change in the pigment melanin content of melanocytes of the iris stroma, thereby to change the color of the eye. Also described are compositions for lightening or darkening the pigmented tissues or treating a pigmented tissue disease.
    Type: Grant
    Filed: November 30, 2011
    Date of Patent: August 29, 2017
    Inventor: Kambiz Thomas Moazed
  • Patent number: 9745574
    Abstract: The present invention relates to RNAi constructs and their use in gene silencing. RNAi constructs associated with the invention contain a double stranded region connected to a single stranded region of phosphorothioate modified nucleotides.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: August 29, 2017
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Tod M. Woolf, Joanne Kamens, William Salomon, Anastasia Khvorova